Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate; ethylcellulose; colloidal anhydrous silica; guar gum; magnesium stearate; disodium edetate - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - sulindac 200mg; sulindac 200mg - tablet - 200 mg - active: sulindac 200mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc quinoline yellow sodium starch glycolate active: sulindac 200mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc quinoline yellow sodium starch glycolate - aclin is indicated for acute or long-term use in the treatment of the following: · osteoarthritis · rheumatoid arthritis · ankylosing spondylitis · periarticular diseases such as acute painful shoulder (acute subacromial bursitis/supraspinatus tendonitis) and tenosynovitis · acute gouty arthritis · painful low back syndrome (low back pain, commonly referred to as lumbago).

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - disulfiram 200mg;  ;   - effervescent tablet - 200 mg - active: disulfiram 200mg     excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose polysorbate 20 povidone purified talc sodium bicarbonate tartaric acid - deterrent to alcohol consumption and an aid in the overall management of selected chronic alcoholic patients involved in an integrated program of counselling and psychiatry. only alcoholic patients who are motivated to abstain from drinking and who are undergoing supportive psychotherapeutic treatment ancillary to a total program of rehabilitation should be selected for antabuse administration.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - amiodarone hydrochloride 200mg;   - tablet - 200 mg - active: amiodarone hydrochloride 200mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc - treatment should be initiated only under hospital or specialist supervision. tachyarrhythmias associated with wolff-parkinson-white syndrome. atrial flutter and fibrillation when other agents cannot be used. all types of tachyarrhythmias of paroxysmal nature including: supraventricular, nodal and ventricular tachycardias, ventricular fibrillation; when other agents cannot be used. tablets are used for stabilisation and long term treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - disodium etidronate 200mg - tablet - 200 mg - active: disodium etidronate 200mg excipient: magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lamotrigine 200mg - chewable/dispersible tablet - 200 mg - active: lamotrigine 200mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium - epilepsy adults (over 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome. bipolar disorder (adults 18 years of age and over) arrow - lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - topiramate 200mg - film coated tablet - 200 mg - active: topiramate 200mg excipient: aniseed flavour 501007 bp0551 lactose magnesium stearate microcrystalline cellulose opadry pink 80w64830 pregelatinised maize starch purified water saccharin sodium sodium starch glycolate - arrow - topiramate is indicated in adults and children 2 years** and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome. **arrow-topiramate tablet range cannot deliver lower doses required for younger paediatric patients .

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - bezafibrate 200mg; bezafibrate 200mg - film coated tablet - 200 mg - active: bezafibrate 200mg excipient: colloidal silicon dioxide macrogols magnesium stearate maize starch microcrystalline cellulose opadry white polyvinyl alcohol purified talc sodium starch glycolate starch titanium dioxide active: bezafibrate 200mg excipient: colloidal silicon dioxide kaolin lactose monohydrate macrogols magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose polysorbate 80 purified talc sodium citrate dihydrate sodium starch glycolate titanium dioxide - - primary hyperlipidaemia types iia, iib, iii, iv and v (fredrickson classification) corresponding to groups i, ii and iii of the european atherosclerosis society guidelines – when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. - secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefotaxime sodium 2096.4mg equivalent to 2000 mg cefotaxime;   - powder for injection - 2000 mg - active: cefotaxime sodium 2096.4mg equivalent to 2000 mg cefotaxime